These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33279260)

  • 1. Effect of Different Rituximab Doses on B Cell Count, Anti-A/B Antibody Titer, Graft Function, and Infectious Complications in ABO-Incompatible Renal Transplantation: A Prospective Study.
    Thukral S; Shinde N; Ray DS
    Transplant Proc; 2021 Apr; 53(3):970-975. PubMed ID: 33279260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation.
    Takahashi K; Saito K; Takahara S; Fuchinoue S; Yagisawa T; Aikawa A; Watarai Y; Yoshimura N; Tanabe K; Morozumi K; Shimazu M;
    Clin Exp Nephrol; 2017 Aug; 21(4):705-713. PubMed ID: 27534951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of 2 Doses of Rituximab on B-Cell and Antidonor Antibody and Outcomes of ABO-Incompatible Living-Donor Pediatric Kidney Transplant.
    Hamasaki Y; Aikawa A; Itabashi Y; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Kawamura T; Sakai K; Shishido S
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):105-109. PubMed ID: 30777532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of rituximab dose according to immunologic risk in ABO-incompatible kidney transplantation.
    Chung BH; Hong YA; Sun IO; Piao SG; Kim JI; Moon IS; Choi BS; Park CW; Kim YS; Yang CW
    Ren Fail; 2012; 34(8):974-9. PubMed ID: 22817654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desensitization with the Use of an Antibody Removal-Free Protocol in ABO-Incompatible Kidney Transplant Recipients with a Low Anti-A/B Antibody Titer.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T
    Transplant Proc; 2018 May; 50(4):982-986. PubMed ID: 29731097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of rituximab dose on infectious complications in ABO-incompatible kidney transplantation.
    Lee J; Lee JG; Kim S; Song SH; Kim BS; Kim HO; Kim MS; Kim SI; Kim YS; Huh KH
    Nephrol Dial Transplant; 2016 Jun; 31(6):1013-21. PubMed ID: 27190360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients.
    Tomita Y; Iwadoh K; Ogawa Y; Miki K; Kato Y; Kai K; Sannomiya A; Koyama I; Kitajima K; Nakajima I; Fuchinoue S
    PLoS One; 2019; 14(10):e0224203. PubMed ID: 31644555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to reduce lethal infectious complications in ABO-incompatible kidney transplantation.
    Choi BH; Cho HK; Jung JH; Choi JY; Shin S; Kim YH; Han DJ
    Transplant Proc; 2015 Apr; 47(3):653-9. PubMed ID: 25891705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABO Incompatible Kidney Transplantation Without B-cell Depletion is Associated With Increased Early Acute Rejection: A Single-Center Australian Experience.
    Bleasel JM; Wan SS; Chadban SJ; Ying T; Gracey DM; Aouad LJ; Chen QA; Utsiwegota M; Mawson J; Wyburn KR
    Transpl Int; 2023; 36():11567. PubMed ID: 37799670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of ABO-incompatible kidney transplantation with ABO-compatible transplantation: A single-center experience from Eastern India.
    Thukral S; Kumar D; Ray DS
    Saudi J Kidney Dis Transpl; 2019; 30(1):97-107. PubMed ID: 30804271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of ABO Blood Type-Incompatible Living-Related Donor Kidney Transplantation Under a Contemporary Immunosuppression Strategy in Japan.
    Hamano I; Hatakeyama S; Fujita T; Murakami R; Hamaya T; Togashi K; Suzuki Y; Yamamoto H; Yoneyama T; Yoneyama T; Hashimoto Y; Narumi S; Tomita H; Ohyama C
    Transplant Proc; 2020; 52(6):1700-1704. PubMed ID: 32448659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation.
    Barnett AN; Manook M; Nagendran M; Kenchayikoppad S; Vaughan R; Dorling A; Hadjianastassiou VG; Mamode N
    Transpl Int; 2014 Feb; 27(2):187-96. PubMed ID: 24188566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Desensitization Allows Pediatric Blood Group Incompatible Kidney Transplantation.
    Stojanovic J; Adamusiak A; Kessaris N; Chandak P; Ahmed Z; Sebire NJ; Walsh G; Jones HE; Marks SD; Mamode N
    Transplantation; 2017 Jun; 101(6):1242-1246. PubMed ID: 27463537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of rituximab dosage for ABO-incompatible living-donor kidney transplantation.
    Nakao T; Ushigome H; Kawai K; Nakamura T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Yoshimura N
    Transplant Proc; 2015 Apr; 47(3):644-8. PubMed ID: 25891703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between response to rituximab and antibody-mediated rejection in ABO-incompatible living kidney transplantation.
    Maenosono R; Unagami K; Kakuta Y; Furusawa M; Okumi M; Azuma H; Ishida H; Tanabe K
    Int J Urol; 2019 Dec; 26(12):1114-1120. PubMed ID: 31522467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable results in ABO-incompatible renal transplantation without B cell-targeted therapy: Advantages and disadvantages of rituximab pretreatment.
    Okada M; Watarai Y; Iwasaki K; Murotani K; Futamura K; Yamamoto T; Hiramitsu T; Tsujita M; Goto N; Narumi S; Takeda A; Morozumi K; Uchida K; Kobayashi T
    Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28792635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption.
    Becker LE; Siebert D; Süsal C; Opelz G; Leo A; Waldherr R; Macher-Goeppinger S; Schemmer P; Schaefer SM; Klein K; Beimler J; Zeier M; Schwenger V; Morath C
    Transplantation; 2015 Nov; 99(11):2364-71. PubMed ID: 25989497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological Analysis in ABO-Compatible and ABO-Incompatible Kidney Transplantation by Performance of 3- and 12-Month Protocol Biopsies.
    Masutani K; Tsuchimoto A; Kurihara K; Okabe Y; Kitada H; Okumi M; Tanabe K; Nakamura M; Kitazono T; Tsuruya K;
    Transplantation; 2017 Jun; 101(6):1416-1422. PubMed ID: 27391195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABO-incompatible transplantation without conventional induction immunosuppression (IL-2RB or depleting agents).
    Hafeeq B; Aziz F; Narayanan S; Aboobacker IN; Gopinathan JC; Narayanan R; Binu JJ; Uvais NA
    Saudi J Kidney Dis Transpl; 2020; 31(3):572-581. PubMed ID: 32655043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High B-cell activating factor is not associated with worse 3-year graft outcome in blood group-incompatible kidney transplantation with rituximab induction.
    Lehnhardt AM; Strecker M; Eiermann T; Marget M; Thaiss F; Nashan B; Koch M
    Clin Transplant; 2015 Apr; 29(4):359-64. PubMed ID: 25627801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.